



November 26, 2013

## **Peregrine Pharmaceuticals Announces Upcoming Events**

TUSTIN, CA -- (Marketwired) -- 11/26/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the following upcoming events.

### *Piper Jaffray 25th Annual Healthcare Conference*

Date: Tuesday, December 3, 2013

Time: 4:00 PM Eastern Time

Location: The New York Palace Hotel, New York, New York

Presenter: Steven W. King, president and chief executive officer

### *Peregrine Pharmaceuticals Second Quarter Fiscal Year 2014 Financial Results*

Date: Tuesday, December 10, 2013

Conference Call: 1:30 PM Pacific Time (4:30 PM Eastern Time)

(877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call

To listen to the live webcast of the Second Quarter Fiscal Year 2014 Financial Results, or access the archived webcast, please visit: <http://ir.peregrineinc.com/events.cfm>.

A replay of the Second Quarter Financial Results call will be available starting approximately two hours after its conclusion through December 17, 2013 by calling (855) 859-2056, or (404) 537-3406 and using passcode 17598749.

### About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ([www.avidbio.com](http://www.avidbio.com)), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at [www.peregrineinc.com](http://www.peregrineinc.com).

### Contact:

Christopher Keenan or Jay Carlson

Peregrine Pharmaceuticals

(800) 987-8256

[info@peregrineinc.com](mailto:info@peregrineinc.com)

Source: Peregrine Pharmaceuticals

News Provided by Acquire Media